Abemaciclib is an oral targeted therapy drug belonging to the class of selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, primarily used to treat hormone receptor-positive (HR+), HER2-negative breast Lesion cells. It works by inhibiting the activity of CDK4 and CDK6, blocking progression from the G1 to the S phase of the cell cycle, thereby inhibiting cell proliferation and growth. Compared to other drugs in the same class, Abemaciclib shows stronger InhibitionInhibition of CDK4 and supports continuous administration, demonstrating good efficacy as a monotherapy. It can be used alone or in combination with endocrine therapy and is suitable for the adjuvant treatment of metastatic and high-risk early-stage disease. Its half-life in the body is approximately 1-2 weeks, and individual differences and drug interactions influence its metabolism. As clinical research continues, the range of applications and treatment strategies for Abemaciclib is constantly evolving.
Abemaciclib, what is it
Abemaciclib powder is an active ingredient (usually in mesylate form) used to treat certain types of disease, particularly hormone receptor-positive (HR+) HER2-negative. Its primary function is to inhibit the growth of these diseased cells. It is a cyclin-dependent kinase (CDK) inhibitor that specifically targets CDK4 and CDK6. CDKs are catalysts that regulate the cell cycle, and their abnormal activity is often closely associated with the progression and spread of diseased cells. It has been approved for use in combination with several other drugs to treat certain types of metastatic or advanced breast-related diseases.
In some cases, it can also be used as a single agent. It is important to note that the specific indications and availability of this drug may change over time. If you or someone you know is considering or receiving treatment containing this ingredient, it is essential to consult a healthcare professional for the most up-to-date and accurate information regarding its uses, potential side effects, and other relevant information based on the latest medical guidelines and research. If you are interested in Abemaciclib, please contact Xi'an Sonwu.
How does Abemaciclib Work
Abemaciclib is an oral targeted therapy that primarily treats hormone receptor-positive (HR+), HER2-negative. It works by blocking key proteins that drive cell division.
Mechanism of Action
1. CDK4/6 InhibitionInhibition
This compound selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These kinases are crucial for cells to progress from the G1 phase to the S phase of the cell cycle.
2. Rb Protein Activation
Normally, CDK4/6 phosphorylates the retinoblastoma (Rb) protein, inactivating it. This product prevents this phosphorylation, keeping the Rb protein active.
3. Cell Cycle Arrest
Active Rb protein inhibits E2F transcription factors, which are necessary for DNA synthesis. This leads to G1 phase cell cycle arrest, preventing cell division.
4. Slowed Lesion Cell Growth
By preventing cell proliferation, the growth rate of Lesion cells slows down or stops. Over time, the cells may undergo senescence or apoptosis.
What Makes Abemaciclib Unique Among CDK4/6 Inhibitors
Stronger Inhibition of CDK4 than CDK6
Continuous dosing (no drug holidays required)
Stronger single-agent activity
Clinical Applications
Can be used alone or in combination with endocrine therapy
Approved for: Metastatic HR+/HER2− breast Lesion cells. (adjuvant therapy).
How long does Abemaciclib stay in the body
This product remains in the body for approximately 1-2 weeks after the last dose. The following is an estimation method:
Half-life
The average elimination half-life of abemaciclib is approximately 18-25 hours.
Elimination from the body
A drug is effectively eliminated after about 5 half-lives.
This means: Most of the drug is eliminated within 4-6 days; near complete elimination: up to 7-10 days;
Abemaciclib has active metabolites, which can slightly prolong its biological effects even as the parent drug concentration decreases. Drug clearance may be slowed if the following conditions exist:
Drug interactions (especially CYP3A inhibitors, grapefruit, etc.)
Renal function has less impact on drug clearance than hepatic function.
Pharmacological effects usually diminish within a few days.
Time in the body: Approximately 1 week, possibly up to 2 weeks in some individuals.
Does Abemaciclib cause weight gain
The answer is that this product does not typically cause weight gain, and weight gain is not a common or expected side effect.
What usually happens?
In clinical trials and real-world use, patients are more likely to experience weight loss than weight gain. This is mainly due to symptoms such as diarrhea (very common), loss of appetite, nausea, and fatigue.
These side effects reduce calorie intake, especially in the early stages of treatment.
What about reports of weight gain?
Some patients do report weight gain, but this is usually indirect, not a direct effect of the medication: weight gain is typically caused by factors such as hormone therapy used in combination with abemaciclib, reduced activity due to fatigue, metabolic changes associated with menopause, or improved appetite after diarrhea is controlled.
The product itself does not cause fat accumulation or slowed metabolism.
If you would like to inquire about the price of abemaciclib powder or other product information, please contact Xi'an Sonwu directly.
Email: sales@sonwu.com
Reference: https://en.wikipedia.org/wiki/Abemaciclib